AAAAAA

   
Results: 1-17 |
Results: 17

Authors: Guichard, S Montazeri, A Chatelut, E Hennebelle, I Bugat, R Canal, P
Citation: S. Guichard et al., Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation, CLIN CANC R, 7(10), 2001, pp. 3222-3228

Authors: Patoux, A Bleyzac, N Boddy, AV Doz, F Rubie, H Bastian, G Maire, P Canal, P Chatelut, E
Citation: A. Patoux et al., Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children, EUR J CL PH, 57(4), 2001, pp. 297-303

Authors: Chatelut, E Pivot, X Otto, J Chevreau, C Thyss, A Renee, N Milano, G Canal, P
Citation: E. Chatelut et al., A limited sampling strategy for determining carboplatin AUC and monitoringdrug dosage, EUR J CANC, 36(2), 2000, pp. 264-269

Authors: Hennebelle, I Terret, C Chatelut, E Bugat, R Canal, P Guichard, S
Citation: I. Hennebelle et al., Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity, ANTI-CANC D, 11(6), 2000, pp. 465-470

Authors: Montazeri, A Boucaud, M Lokiec, F Pinguet, F Culine, S Deporte-Fety, R Albin, N Laguerre, B Goupil, A Bugat, R Canal, P Chatelut, E
Citation: A. Montazeri et al., Population pharmacokinetics of topotecan: intraindividual variability in total drug, CANC CHEMOT, 46(5), 2000, pp. 375-381

Authors: Guimbaud, R Guichard, S Dusseau, C Bertrand, V Aparicio, T Lochon, I Chatelut, E Couturier, D Bugat, R Chaussade, S Canal, P
Citation: R. Guimbaud et al., Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans, CANC CHEMOT, 45(6), 2000, pp. 477-482

Authors: Terret, C Erdociain, E Guimbaud, R Boisdron-Celle, M McLeod, HL Fety-Deporte, R Lafont, T Gamelin, E Bugat, R Canal, P Chatelut, E
Citation: C. Terret et al., Dose and time dependencies of 5-fluorouracil pharmacokinetics, CLIN PHARM, 68(3), 2000, pp. 270-279

Authors: Chatelut, E Canal, P Bugat, R
Citation: E. Chatelut et al., Pharmacokinetics and dose adjustment of carboplatin, B CANCER, 87, 2000, pp. 17-23

Authors: Simeon, N Chatelut, E Canal, P Nertz, M Couderc, F
Citation: N. Simeon et al., Anthracycline analysis by capillary electrophoresis - Application to the analysis of daunorubicine in Kaposi sarcoma tumor, J CHROMAT A, 853(1-2), 1999, pp. 449-454

Authors: Perdaems, N Caunes, N Canal, P Chatelut, E
Citation: N. Perdaems et al., Possible excretion at etoposide via the intestinal mucosa, CANC CHEMOT, 43(6), 1999, pp. 520-521

Authors: Tranchand, B Amsellem, C Chatelut, E Freyer, G Iliadis, A Ligneau, B Trillet-Lenoir, V Canal, P Lochon, I Ardiet, CJ
Citation: B. Tranchand et al., A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients, CANC CHEMOT, 43(4), 1999, pp. 316-322

Authors: Chatelut, E Rostaing, L Gregoire, N Payen, JL Pujol, A Izopet, J Houin, G Canal, P
Citation: E. Chatelut et al., A pharmacokinetic model for alpha interferon administered subcutaneously, BR J CL PH, 47(4), 1999, pp. 365-371

Authors: Gladieff, L Chatelut, E Gaspard, MH Skaf, R de Forni, M Mihura, J Canal, P Bugat, R
Citation: L. Gladieff et al., Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study, B CANCER, 86(7-8), 1999, pp. 673-677

Authors: Canal, P Gautie, L Gregoire, N Perdaems, N Chatelut, E
Citation: P. Canal et al., News on the pharmacokinetics of anticancer drags, B CANCER, 86(1), 1999, pp. 85-89

Authors: Guichard, S Terret, C Hennebelle, I Lochon, I Chevreau, P Fretigny, E Selves, J Chatelut, E Bugat, R Canal, P
Citation: S. Guichard et al., CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues, BR J CANC, 80(3-4), 1999, pp. 364-370

Authors: Perdaems, N Bachaud, JM Rouzaud, P Murris-Espin, M Hermant, C Mihura, J Lochon, I Houin, G Canal, P Chatelut, E
Citation: N. Perdaems et al., Relation between unbound plasma concentrations and toxicity in a prolongedoral etoposide schedule, EUR J CL PH, 54(9-10), 1998, pp. 677-683

Authors: Canal, P Chatelut, E Guichard, S
Citation: P. Canal et al., Practical treatment guide for dose individualisation in cancer chemotherapy, DRUGS, 56(6), 1998, pp. 1019-1038
Risultati: 1-17 |